Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17 alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III

• Autor(a) principal: Silva, R. D.
• Data de Publicação: 2000
• Outros Autores: Kater, Claudio Elias [UNIFESP], Dib, Sergio Atala [UNIFESP], Laureti, S., Forini, F., Cosentino, A., Falorni, A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: https://doi.org/10.1530/eje.0.1420187; http://repositorio.unifesp.br/handle/11600/43587

Objective: To evaluate the frequency of autoantibodies (Ab) against 21 hydroxylase (210H), side-chain cleavage (SCC) and 17 alpha-hydroxglase (17OH), in Addison's disease (AD) and autoimmune polyendocrine syndrome type III (APSIII), Design and Methods: We used radiobinding assays and in vitro translated recombinant human S-35-21OH, S-35-SCC or S-35-17OH and studied serum samples from 29 AD (18 idiopathic, 11 granulomatous) and 18 APSIII (autoimmune thyroid disease plus type 1 diabetes mellitus, without AD) patients. Results were compared with those of adrenocortical autoantibodies obtained with indirect immunofluorescence (ACA-IIF). Results: ACA-IIF were detected in 15/18 (83%) idiopathic and in 1/11 (9%) granulomatous AD subjects. 21OHAb were found in 14/18 (78%) idiopathic and in the same (9%) granulomatous AD subject. A significant positive correlation was shown between ACA-IIF and 21OHAb levels (r(2) = 0.56, P < 0.02). The concordance rate between the two assays was 83% (24/29) in AD patients. SCCAb were found in 5/15 (28%) idiopathic (4 of whom were also positive for 21OHAb) and in the same (9%) granulomatous AD subject, 170HAb were found in only 2/18 (11%) idiopathic and none of the granulomatous AD patients. Two APSIII patients were positive for ACA-IIE but only one was positive for 210HAb and SCCAb. 170HAb were found in another two APSIII patients. Conclusions: Measurement of 210HAb should be the first step in immune assessment of patients with AD and individuals at risk for adrenal autoimmunity, in addition to ACA-IIF. Due to their low prevalence in AD, measurement of SCCAb and 170HAb should be indicated only for 210HAb negative patients and/or for those with premature ovarian failure, regardless of ACA-IIF results.